Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Bin Xiao"'
Publikováno v:
Biological and Pharmaceutical Bulletin. 43:1046-1051
Beta-asarone (β-Asarone), the major component of Acorus tatarinowii Rhizoma, has been proved to be muti-pharmacological activities including anti-inflammation, and which is effective in protecting the central nervous system. However, the effect of
Autor:
Jing Su, Xiao-Ying Ji, Yina Wang, Bin Xiao, Xudong Xiang, Shaokun Liu, Guyi Wang, Haiyun Dong, Xianghong Yan, Su-bo Gong
Publikováno v:
Mediators of Inflammation, Vol 2021 (2021)
Mediators of Inflammation
Mediators of Inflammation
Background and Purpose. Allergic asthma, a respiratory disease with high morbidity and mortality, is reported to be related to the airway allergic inflammation and autophagy-induced oxidative stress. Although the therapeutic effects of fermentate pre
Autor:
Xijing Zhang, Dandan Cheng, Jiajia Wang, Haixing Zhong, Zhenhua Jiang, Zongping Fang, Ting Gu, Wugang Hou, Bin-Xiao Su, Yi Li, Haiyun Guo, Shiquan Wang
Publikováno v:
Brain research. 1757
Rosmarinic acid (RA), a natural polyphenol, possesses potent antioxidant and anti-inflammatory activities. To evaluate the ability of RA to cure ischemic stroke and post-stroke depression (PSD), rats were treated with various doses of RA after cerebr
Autor:
Youping Liu, Jinju Wang, Ying Cheng, Run Chen, Chunyan Duan, Chunhong Feng, Rongyang Dai, Bin Xiao, Hong Li, Fuli Yao, Hong Zhou, Jing Li, Chunyan Zhang, Xiaofang Zhao
Publikováno v:
Oncotarget
// Xiaofang Zhao 1, * , Chunyan Zhang 1, * , Hong Zhou 1, * , Bin Xiao 1 , Ying Cheng 1 , Jinju Wang 2 , Fuli Yao 1 , Chunyan Duan 1 , Run Chen 3 , Youping Liu 2 , Chunhong Feng 2 , Hong Li 1 , Jing Li 2 , Rongyang Dai 1 1 Department of Biochemistry
Publikováno v:
International Journal of Molecular Medicine
In the present study, we investigated the role of activating transcription factor 6 (ATF6) in the mechanism by which chronic intermittent hypoxia (CIH) increases tolerance to myocardial ischemia/reperfusion (I/R). Experiments were conducted using a r
Publikováno v:
The Journal of thoracic and cardiovascular surgery. 157(2)
Objective The aim of the study was to examine whether the cannabinoid agonist WIN55212-2 could attenuate ischemic spinal cord injury (SCI) in rats through inhibition of GAPDH/Siah1 signaling. Methods Male Sprague-Dawley rats were distributed randomly
Publikováno v:
Chinese Journal of Cancer. 29:741-746
BACKGROUND AND OBJECTIVE Rosiglitazone is a peroxisome proliferators-activated receptor gamma (PPARgamma) ligand, which inhibits tumor growth by activating PPARgamma signaling pathways. Fluorouracil (5-FU) is one of the commonly used chemotherapeutic
Autor:
James W. Voltz, Guangtian Yang, Dao Wen Wang, Bin Xiao, Xuguang Li Li, Xuefeng Yu, Jiangtao Yan, Darryl C. Zeldin, Xiao Xiao
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 334:784-794
Cytochrome P450 (P450)-derived epoxyeicosatrienoic acids (EETs) exert well recognized vasodilatory, diuretic, and tubular fluid-electrolyte transport actions that are predictive of a hypotensive effect. The study sought to determine the improvement o
Autor:
Jing Zhang, Hai-Xing Mai, Lei Wang, Ke Zheng, Jia-Ning Wang, Zhi-Fang Li, Xiu-Bin Xiao, Wei-Jing Zhang, Hua You, Li Wei, Yuan Liu, Zai-Liang Yang, Wan-Liang Sun, Yan-Qing Wang, Feng Liang
Publikováno v:
Journal of Translational Medicine
Background At present, no effective clinical treatment is available for the late effects of radiation myelopathy. The aim of the present study was to assess the therapeutic effects of human umbilical cord-derived mesenchymal stromal cells (UC-MSCs) i
Autor:
Christina L. Addison, James Villeneuve, Khalid N. Al-Zahrani, Grant A. Howe, Mohamed Shaad Hasim, Bin Xiao, Luc A. Sabourin, Glenwood D. Goss, Huijun Zhao, Harmanjatinder S. Sekhon, Jim Dimitroulakos
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 3, p e0150567 (2016)
PLoS ONE, Vol 11, Iss 3, p e0150567 (2016)
Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic target for non-small cell lung cancers (NSCLC). As patients with wild-type EGFR have demonstrated only modest benefit from EGFR tyrosine kinase inhibitors (TK